Fernando Fervenza, MD
Nephrology · Rochester, MNNPI 1356313522
Payments from drug & device makers
Across 209 payments — averaging $8177.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$706K
- Genentech, Inc.$525K
- Travere Therapeutics, Inc.$106K
- Morphosys AG$98K
- Mallinckrodt Hospital Products Inc.$86K
- Alnylam Pharmaceuticals Inc.$84K
- plus $104K from 16 others
Across 2 payments — averaging $718.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 32 | $705,899 |
| Genentech, Inc. | 45 | $525,188 |
| Travere Therapeutics, Inc. | 48 | $106,245 |
| Morphosys AG | 2 | $98,112 |
| Mallinckrodt Hospital Products Inc. | 2 | $85,590 |
| Alnylam Pharmaceuticals Inc. | 20 | $84,487 |
| Amgen | 4 | $20,494 |
| AstraZeneca | 11 | $19,079 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $14,500 |
| Biocryst Pharmaceuticals, Inc. | 9 | $9,980 |
| Boehringer Ingelheim International GmbH | 10 | $8,495 |
| Novartis | 2 | $6,305 |
| Biogen | 1 | $5,679 |
| Vertex | 7 | $4,875 |
| GSK | 2 | $3,741 |
| Mallinckrodt Enterprises LLC | 1 | $2,750 |
| Boehringer Ingelheim | 1 | $2,600 |
| Astellas Pharma Inc | 2 | $2,318 |
| Tanabe Pharma America, Inc. | 1 | $1,950 |
| Argenx US, Inc. | 1 | $550 |
| Calliditas Therapeutics US Inc. | 3 | $158 |
| Aurinia Pharma U.S., Inc. | 1 | $72 |
How this compares
$1,709,066 in reported general payments places this provider in the 95th percentile of 208 nephrology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Rochester
- John LieskeRochester$2.4M
- Nattawat KlomjitRochester$1.5M
- Neera DahlRochester$1.4M
- Vicente TorresRochester$661K
- Carrie SchinstockRochester$488K
- Ladan ZandRochester$284K
- Kianoush Banaei KashaniRochester$253K
- Rajiv KumarRochester$198K
- John DillonRochester$176K
- Timothy LarsonRochester$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.